Skip to main content
Log in

The effectiveness of dapiprazole in preventing exercise-induced IOP increase in patients with pigmentary dispersion syndrome

  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose. The authors investigated the use of dapiprazole, an alpha-adrenergic blocking agent, in preventing pigment release and IOP increase after exercise in patients affected with PDS. Methods. Three young myopic males (31, 34 and 35 years old) affected with pigmentary dispersion syndrome performed 30 minutes of jogging on a computerized treadmill. Telemetric heartbeat measurement was performed to obtain constant pulse rate training. Computerized tonography and IOP measurement were performed 10 minutes after the exercise. After one month the patients repeated the same exercise after pre-treatment with dapiprazole 0.5% eyedrops (one drop 30, 20 and 10 minutes before the exercise). Ten minutes after the exercise IOP measurements and computerized tonography were repeated. Results. After 30 minutes of exercise IOP measurements showed values ranging from 19 to 45 mmHg (mean 30.33; SD 8.73). Computerized tonography C values after exercise ranged from 0.04 to 0.16 (mean 0.09; SD 0.04). After pre-treatment with dapiprazole 0.5% eyedrops, IOP values ranged from 18 to 28 mmHg (mean 23.33; SD 3.44) and tonography C values ranged from 0.10 to 0.20 (mean 0.14; SD 0.03). Conclusions. The study supports the concept that exercise-induced pigment release temporarily obstructs the acqueous outflow channels, causing IOP increase in some patients with PDS. Pre-treatment with dapiprazole was useful in reducing IOP spikes and in increasing tonographic total outflow facility after exercise. The absence of induced myopia and the lack of dangerous vitreoretinal tractions on retinal periphery make dapiprazole a safe method to reduce exercise-induced pigment dispersion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Sugar, HS, Barbour, FA. Pigmentary glaucoma: a rare clinical entity. Am J Ophthalmol 1949; 32: 90–2.

    Google Scholar 

  2. Bick, MW. Pigmentary glaucoma in females. Arch Ophthalmol 1957; 58: 483–94.

    Google Scholar 

  3. Scheie, HG, Fleischhauer, HW. Idiopatic atrophy of the epithelial layers of the iris and ciliary body: a clinical study. Arch Ophthalmol 1958; 59: 216–28.

    Google Scholar 

  4. Sugar, HS. Pigmentary glaucoma: a 25-year review. Am J Ophthalmol 1966; 62: 499–507.

    Google Scholar 

  5. Lichter, PR, Shaffer, RN. Diagnostic and prognostic signs in pigmentary glaucoma. Trans Am Acad Ophthalmol Otolaryngol 1970; 74: 984–98.

    Google Scholar 

  6. Campbell, DG. Pigmentary dispersion and glaucoma: a new theory. Arch Ophthalmol 1970; 97: 1667–72.

    Google Scholar 

  7. Schenker, HI, Luntz, MH, Kels, B, Podos, SM. Exercise-induced increase in intraocular pressure in the pigmentary dispersion syndrome. Am J Ophthalmol 1980; 89: 598–600.

    Google Scholar 

  8. Epstein, DL, Boger III, WP, Morton Grant, W. Phenylephrine provocative testing in the pigmentary dispersion syndrome. Am J Ophthalmol 1978; 85: 43–50.

    Google Scholar 

  9. Haynes, WL, Tim Johnson, A, Alward, WLM. Inhibition of exercise-induced pigment dispersion in a patient with the pigmentary dispersion syndrome. Am J Ophthalmol 1990; 109: 601–2.

    Google Scholar 

  10. Haynes, WL, Alward, WLM, Tello, C, Liebmann, JM, Ritch, R. Incomplete elimination of exercise-induced pigment dispersion by laser iridotomy in pigment dispersion syndrome. Ophthalmic Surg Lasers 1995; 26: 484–6.

    Google Scholar 

  11. Haynes, WL, Tim Johnson, A, Alward, WLM. Effects of jogging exercise on patients with the pigmentary dispersion syndrome and pigmentary glaucoma. Ophthalmology 1992; 99: 1096–103.

    Google Scholar 

  12. Jensen, PK, Nissen, O, Kessing, SV. Exercise and reversed pupillary block in pigmentary glaucoma. Am J Ophthalmol 1995; 120: 110–2.

    Google Scholar 

  13. Ritch, R. Pigmentary glaucoma: a self limited entity? Ann Ophthalmol 1983; 15: 115–6.

    Google Scholar 

  14. Scheie, HG, Cameron, JD. Pigment dispersion syndrome: a clinical study. Br J Ophthalmol 1981; 65: 264–9.

    Google Scholar 

  15. Weseley, P, Liebmann, J, Walsh, JB, Ritch, R. Lattice degeneration of the retina and the pigment dispersion syndrome. Am J Ophthalmol 1992; 114: 539–43.

    Google Scholar 

  16. Speakman, JS. Pigmentary dispersion. Br J Ophthalmol 1981; 65: 249–51.

    Google Scholar 

  17. Gallenga, PE, Mastropasqua, L. Dapiprazole in pigmentary glaucoma. New Trends In Ophthalmol 1989; 3: 193–6.

    Google Scholar 

  18. Reibaldi, A. A new alpha-blocking agent. Glaucoma 1984; 6: 255–7.

    Google Scholar 

  19. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma. Ophthalmic Surg Lasers. In press.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mastropasqua, L., Carpineto, P., Ciancaglini, M. et al. The effectiveness of dapiprazole in preventing exercise-induced IOP increase in patients with pigmentary dispersion syndrome. Int Ophthalmol 19, 359–362 (1995). https://doi.org/10.1007/BF00130855

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00130855

Key words

Navigation